<SEC-DOCUMENT>0001140361-26-000715.txt : 20260108
<SEC-HEADER>0001140361-26-000715.hdr.sgml : 20260108
<ACCEPTANCE-DATETIME>20260108160540
ACCESSION NUMBER:		0001140361-26-000715
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260108
FILED AS OF DATE:		20260108
DATE AS OF CHANGE:		20260108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		26519642

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ef20062541_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Report of Foreign Private</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Issuer Pursuant to Rule</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">13a-16 or 15d-16 of the</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Securities Exchange Act</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">of 1934</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">For the month of January 2026</div>
      <div style="text-align: center; color: #000000;">Commission File</div>
      <div style="text-align: center; color: #000000;">Number: 001-38283</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">InflaRx N.V.</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Winzerlaer Str. 2</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">07745 Jena,</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Germany</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">(+49) 3641508180</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000;">(Address of principal executive offices)</div>
      <div><br>
      </div>
      <div style="color: #000000;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000;">Form 20-F &#9746; Form 40-F &#8201;&#9744;</div>
      <div><br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">INCORPORATION BY REFERENCE</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="color: #000000;">On January 8, 2026, InflaRx N.V. (the &#8220;Company&#8221;) issued a press release titled</font> &#8220;<font style="color: #000000;">InflaRx&#160; Announces Strategy&#160; Focused on Capital-Efficient Execution
          with Izicopan and Near-Term Value Creation.&#8221;</font></div>
      <div><br>
      </div>
      <div>
        <div style="text-align: justify;">The Company today announced it is undertaking measures to reduce spending, extend the Company&#8217;s cash runway, and align resources to enable further
          development of izicopan in hidradentis suppurativa and other inflammation and immunology indications as a potential best-in-class C5aR inhibitor and pipeline-in-a-product.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">
        <div>The Company has initiated a workforce reduction of approximately 30% and substantial spending reductions, including significant reductions in Gohibic
          (vilobelimab) commercial spending and related functions. The Company estimates these activities will result in a one-time charge of approximately $7 million. The majority of this charge will be a non-cash charge related to the write-off of
          vilobelimab inventory, with a smaller portion associated with the restructuring, including personnel-related costs and the termination or modification of certain third-party contracts. Upon completion, The Company expects a significantly leaner
          cost structure, enabling substantial and sustained reductions in operating expenses and a meaningful extension of its cash runway to mid-2027.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">The Company will maintain the operational capability needed to support the ongoing BARDA &#8220;Just Breathe&#8221; Phase 2 clinical platform study in ARDS and does not expect these actions to negatively impact
        the trial. The Company will keep Gohibic (vilobelimab) available for ordering inside the U.S. under its emergency use authorization and maintain the ability to satisfy Gohibic (vilobelimab) demand in the U.S. on a reactive basis.</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">The Company will continue to review partnering opportunities for Gohibic (vilobelimab) in the U.S. and Europe. In addition, as previously disclosed, the Company anticipates meeting with the U.S. Food
        and Drug Administration to determine a potential development path forward for vilobelimab in pyoderma gangrenosum, which it anticipates would only be conducted in collaboration with a partner.</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">This report on Form 6-K (the &#8220;Report&#8221;) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration
        statement on Form F-3 (File No. 333-273058) of the Company and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">A copy of the press release is attached as Exhibit 99.1 to this Report. Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
        &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</div>
      <div><br>
      </div>
      <div style="color: #000000; font-weight: bold;"><u>FORWARD-LOOKING STATEMENTS</u></div>
      <div><br>
      </div>
      <div style="color: #000000;">This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
        &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; among others. Forward-looking statements appear in a number of places throughout this Report and may include statements
        regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, &#8220;Risk factors&#8221; and &#8220;Cautionary statement regarding forward-looking statements,&#8221; in
        our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
        performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue
        reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z21f15509e7cd487d9a7f1802678bf766" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 20%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 80%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="color: rgb(0, 0, 238);"><a href="ef20062541_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Press Release, dated January 8, 2026</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
      <div><br>
      </div>
      <div style="color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z75068c8eb98140178405cecd147f73c4" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 40%; vertical-align: top;"><br>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">INFLARX N.V.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Date: January 8, 2026</div>
            </td>
            <td style="width: 5%; vertical-align: top;"><br>
            </td>
            <td style="width: 55%; vertical-align: top;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 55%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; color: rgb(0, 0, 0);">/s/ Niels Riedemann</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;"><br>
            </td>
            <td style="width: 55%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Name: Niels Riedemann</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;"><br>
            </td>
            <td style="width: 55%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Title: Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20062541_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; margin-left: 18pt;"><font style="font-weight: bold;"> Exhibit 99.1</font><br>
      </div>
      <div> <br>
      </div>
      <div><img src="image00001.jpg"> </div>
      <div style="text-align: center; margin-left: 18pt;"> <br>
      </div>
      <div style="text-align: center; margin-left: 18pt;">InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z7229c95150074f3780852cb911533377" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6d16d61d51f24491bdb5b3a8f76cc089" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To broaden signal-finding activities for izicopan in additional I&amp;I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and
                additional geographies</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zee7e7b003afe4328a03eedcf982884d3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Toward the goal of fast-tracking izicopan development across all applicable I&amp;I indications, InflaRx continues its concurrent strategy to foster discussions with potential collaborators</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zc6272aafc56a4f93a47a053cf65ab144" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>InflaRx is executing an approximately 30% workforce reduction, leading to a significant reduction of the Company&#8217;s cost structure, and extension of its cash runway to mid-2027</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z55f02f63c2214d54a46cdf6d9e3310dc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Company intends to host a virtual Capital Markets Day to highlight the clinical utility and commercial potential of izicopan in HS and I&amp;I broadly in spring 2026</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;"><font style="font-weight: bold;">Jena, Germany, January 8, 2026</font>&#8211; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the
        complement system, today announced it is undertaking measures to reduce spending, extend the Company&#8217;s cash runway, and align resources to enable further development of izicopan in HS and other I&amp;I indications as a potential best-in-class C5aR
        inhibitor and pipeline-in-a-product.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;"><font style="font-weight: bold;">Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx</font>, commented: &#8220;In an effort to enable the long-term success of InflaRx we have made
        the decision to increase our capital efficiency and tightly focus the Company. Our goal with this realignment is to prioritize resources toward izicopan in hidradenitis suppurativa and additional areas in inflammation and immunology, allowing us to
        maximize its value as a significantly differentiated oral inhibitor of C5aR and pipeline-in-a-product. We are very optimistic about our strategy and the sizable potential of izicopan, and look forward to reporting additional progress during the
        year.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Restructuring and reduction in Gohibic (vilobelimab) spending</div>
      <div style="text-align: justify; margin-right: 3.6pt;">As part of its strategic focusing, InflaRx is streamlining its organizational structure and largely discontinuing non-essential activities outside the development of izicopan. These actions are
        designed to sharpen the Company&#8217;s strategic execution, concentrate resources on its highest-value asset, and materially improve capital efficiency.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;">InflaRx has initiated a workforce reduction of approximately 30% and substantial spending reductions, including significant reductions in Gohibic (vilobelimab) commercial spending and related
        functions. The Company estimates these activities will result in a one-time charge of approximately $7 million. The majority of this charge will be a non-cash charge related to the write-off of vilobelimab inventory, with a smaller portion
        associated with the restructuring, including personnel-related costs and the termination or modification of certain third-party contracts. Upon completion, InflaRx expects a significantly leaner cost structure, enabling substantial and sustained
        reductions in operating expenses and a meaningful extension of its cash runway to mid-2027.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00001.jpg"> </div>
        </div>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;">InflaRx will maintain the operational capability needed to support the ongoing BARDA &#8220;Just Breathe&#8221; Phase 2 clinical platform study in ARDS and does not expect these actions to negatively impact
        the trial. InflaRx will keep Gohibic (vilobelimab) available for ordering inside the US under its emergency use authorization and maintain the ability to satisfy Gohibic (vilobelimab) demand in the US on a reactive basis.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;">InflaRx will continue to review partnering opportunities for Gohibic in the US and Europe. In addition, as previously disclosed, the Company anticipates meeting with the FDA to determine a
        potential development path forward for vilobelimab in pyoderma gangrenosum, which it anticipates would only be conducted in collaboration with a partner.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Enabling broader development with izicopan (INF904) in I&amp;I</div>
      <div style="text-align: justify; margin-right: 3.6pt;">Given data demonstrating its advantageous PK/PD profile, meaningful differentiation as an inhibitor of the C5a/C5aR axis, and potential to address HS, chronic spontaneous urticaria (CSU) and
        other I&amp;I indications, the Company will prioritize resource allocation and clinical development toward izicopan while continuing active dialog with potential partners across all geographies to expedite and maximize value.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;">In HS InflaRx continues to make progress toward Phase 2b readiness. InflaRx is in active dialogue with the FDA related to the Phase 2b study design and potential endpoints. The aim is to align on
        a development path and endpoints expected to meaningfully differentiate izicopan from existing therapies, while also addressing variability inherent in some HS trial outcomes. InflaRx is moving as quickly as is feasible in this effort and intends
        to provide an update on its HS Phase 2b planning and readiness in due course.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;">InflaRx sees significant potential for izicopan to address unmet needs in multiple I&amp;I indications beyond HS, including CSU, where InflaRx continues data analysis and active dialog with
        thought leaders to determine next steps. Given the supportive nature of the Phase 2a data collected to-date from the two main CSU (all-comer) dosing cohorts, and low enrollment trends in the third (anti-IgE refractory) dosing cohort, InflaRx has
        decided to close the third treatment cohort. InflaRx will utilize the existing data set to determine next steps for izicopan in CSU, which the Company expects to communicate later this year.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;">InflaRx intends to submit the izicopan Phase 2a datasets in HS and CSU for presentation at medical conferences later this year.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt;">Toward the goal of generating proof of concept data in additional I&amp;I indications as efficiently as possible, InflaRx intends to conduct a PK bridging study with izicopan in China this year
        in order to expedite subsequent proof of concept studies in China and elsewhere. The Company intends to provide an update on these efforts, and on efforts in additional potential I&amp;I indications, later this year.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00001.jpg"> </div>
        </div>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Capital Markets Day</div>
      <div style="text-align: justify; margin-right: 3.6pt;">InflaRx expects to host a virtual capital markets day this spring. During this event the Company plans to highlight the clinical utility of izicopan in HS and I&amp;I more broadly, including
        izicopan&#8217;s role in respective I&amp;I treatment algorithms, and its emerging commercial potential.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt; font-style: italic; font-weight: bold;">About izicopan</div>
      <div style="text-align: justify;">Izicopan (INF904) is an orally administered, small molecule inhibitor of the C5a receptor Ca5R1 that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies.
        Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan has minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important role in the metabolism of a variety of metabolites
        and drugs, including glucocorticoids. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple
        doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a &#8805;90% blockade of C5a-induced neutrophil activation achieved over the 14-day
        dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful
        reductions in abscesses and nodules (ANs) and draining tunnels (dTs), robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the
        potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved
        disease control as measured by the Urticaria Control Test (UCT7).</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt; font-style: italic; font-weight: bold;">About InflaRx N.V.</div>
      <div style="text-align: justify;">InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and
        specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx&#8217;s lead program is izicopan (INF904), an
        orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing
        izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds
        to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.<br>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and
        InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt; font-style: italic; font-weight: bold;">Contacts:</div>
      <table cellspacing="0" cellpadding="0" border="0" id="za7b2ee3a2e484bd18484af02e300c40c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt; font-weight: bold;">InflaRx N.V.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt; font-weight: bold;">MC Services AG</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Jan Medina, CFA</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Katja Arnold, Laurie Doyle, Dr. Regina Lutz</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; margin-right: 3.7pt;">Vice President, Head of Investor Relations</div>
            </td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; margin-right: 3.7pt;">Email: <u>inflarx@mc-services.eu</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; margin-right: 3.7pt;">Email: <u>IR@inflarx.de</u></div>
            </td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; margin-right: 3.7pt;">Europe: +49 89-210 2280</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1"><br>
            </td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; margin-right: 3.7pt;">U.S.: +1-339-832-0752</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00001.jpg"> </div>
        </div>
      </div>
      <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">FORWARD-LOOKING STATEMENTS</div>
      <div style="text-align: justify;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
        &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; among others. Forward-looking statements appear in a number of places throughout this press release and may include statements
        regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things: the receptiveness of izicopan as a treatment for&#160;HS and CSU by patients and hospitals and related treatment recommendations
        by medical/healthcare institutes and other third-party organizations; our ability to successfully secure distribution channels and commercialize GOHIBIC (vilobelimab) as a treatment for COVID-19 patients and our ability to positively influence
        treatment recommendations by U.S. and European hospitals, guideline bodies and other third-party organizations; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated
        returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab) in its approved or authorized indication or for vilobelimab and any other product candidates, under the Emergency Use Authorization and in the future if approved for
        commercial use in the United States, Europe or elsewhere; our ability to successfully implement The InflaRx Commitment Program, the success of our future clinical trials for vilobelimab&#8217;s treatment of debilitating or life-threatening inflammatory
        indications, including acute respiratory distress syndrome and other indications, and any other product candidates, including izicopan, and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and
        clinical trials; the timing, progress and results of pre-clinical studies and clinical trials of vilobelimab, izicopan and any other product candidates, including for the development of vilobelimab in several indications, including to obtain full
        approval of GOHIBIC (vilobelimab) for COVID-19 and other virally induced ARDS, to treat HS and CSU, and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the
        results of the trials will become available, the costs of such trials and our research and development programs generally&#894; our interactions with and the receptiveness and approval by regulators regarding the results of clinical trials and potential
        regulatory approval or authorization pathways, including our biologics license application submission for GOHIBIC (vilobelimab); the timing and outcome of any discussions or submission of filings for regulatory approval or authorization of
        vilobelimab, izicopan or any other product candidate, and the timing of and our ability to obtain and maintain full regulatory approval, the EUA and/or market authorization of vilobelimab or GOHIBIC (vilobelimab) for any indication; our ability to
        leverage our proprietary anti-C5a and anti-C5a receptor technologies to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property
        protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection; whether the U.S. Food and Drug Administration, the European Medicines Agency or any comparable foreign regulatory authority will accept or
        agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; the success of our future clinical trials for vilobelimab, izicopan and any other product
        candidates and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; our expectations regarding the size of the patient populations for, the market opportunity for, the medical
        need for and clinical utility of vilobelimab, izicopan or any other product candidates, if approved or authorized for commercial use; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and
        processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical
        trials and for commercial supply of vilobelimab and for the finished product GOHIBIC (vilobelimab) in the United States and Europe; our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to
        obtain additional financing; our expectations regarding the scope of any approved indication for vilobelimab; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved or
        authorized, any commercial sales; if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory overview; our ability to comply with
        enacted and future legislation in seeking marketing approval or authorization and commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; our
        competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors and other therapeutic products being developed in similar medical conditions in which vilobelimab, izicopan or any
        other of our product candidates is being developed or our industry; and the risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in our periodic filings with the U.S. Securities and Exchange Commission. These statements
        speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results,
        performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update
        these forward-looking statements, even if new information becomes available in the future, except as required by law.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  Z *$# 2(  A$! Q$!_\0
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M%_A[?W%Y')K2?9[2,Y,98%G]N.@J/5O FMW>KW,Z01"%Y6* 2 87/'Z4 /\
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ITU+3M=O-,N=.G830+:RR,T<G1N&11@@#OU%>M444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
